Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Understanding SLT Meaning: What Selective Laser Trabeculoplasty Does

Posted by: Northwest Eye in SLT meaning on September 7, 2025

What SLT means in eye care

SLT means selective laser trabeculoplasty. It is a laser procedure used to lower pressure inside the eye.

SLT has been an FDA-approved standard treatment for open-angle glaucoma since 2001. Lowering pressure can be part of a plan to manage glaucoma, but SLT is not a cure for glaucoma. The term identifies a treatment, not a personal recommendation. An ophthalmologist considers the type of glaucoma, pressure measurements, drainage angle, optic nerve findings, prior treatment, and response to care before discussing it. The abbreviation alone cannot show whether SLT fits your eyes or whether you will still need medicine. The available patient profile comes from one retrospective study, so it does not show how common SLT is in the general population or who most often receives it in every setting. Its figures describe one study period and setting rather than use in all clinics.

A retrospective study analyzed 6,081 SLT treatments in 4,601 eyes of 2,812 patients after excluding miscoded and incomplete records. In that study, primary SLT use rose from 3.5% of treatments in 2014 to 17.2% in 2018, while the number of SLT-treated eyes tripled. Those figures describe that study population and period, not every eye-care practice. In the same study population, 65% of participants were women, 98% were White, and the median age was 71. High myopia, defined as SE ≤−5.0 D, was present in 14% of eyes, and 31% of eyes were pseudophakic. These details further show why the study figures should not be treated as a profile of every person considered for SLT.

The same study reports permanent vision loss in fewer than 0.2 per 1,000 SLT treatments. That figure describes the study’s reported rate of permanent vision loss after treatment; it does not predict your personal result.

What SLT is used to treat

SLT is used to lower eye pressure in glaucoma. Your ophthalmologist may discuss it as a primary treatment or as an addition to glaucoma medicine. The goal is to improve pressure control through the eye’s natural drainage system.

Clinical trials reported that SLT reduced eye pressure by 20% to 30% and had a favorable safety profile with minimal structural damage. The 20% to 30% figure measures the reported reduction in eye pressure in those clinical trials; it is not a guaranteed change for every eye.

A review reports that SLT was successful in about 80% of patients and lowered eye pressure by as much as 20% to 30% on average. The 80% figure describes the share of patients classified as successful in that review, while the 20% to 30% figure measures the average amount of pressure reduction reported. The review does not make either figure a promise about your treatment.

SLT may be discussed as a first-line treatment for glaucoma.

How SLT lowers eye pressure

The trabecular meshwork is the eye’s natural drainage area. During SLT, your doctor directs low-energy laser light at this tissue. The drainage area sits near the front of the eye, where fluid leaves the eye.

SLT targets specific pigmented cells in the drainage area while leaving surrounding tissue intact. This selective approach differs from older laser treatment that caused more heat-related tissue damage. Preserving the drainage tissue is also why SLT can be repeated when the first treatment was effective.

By improving fluid drainage through the eye’s natural pathway, SLT lowers eye pressure. The exact biological mechanism remains uncertain; it may involve changes in the trabecular meshwork that improve fluid outflow. You can think of the treatment as helping the eye use its existing drainage route more effectively.

A retrospective study of SLT-treated eyes included several glaucoma diagnoses. Primary open-angle glaucoma accounted for 45% of eyes, normal-tension glaucoma accounted for 22%, and exfoliation glaucoma accounted for 20%. These percentages describe the diagnoses among eyes in that study population, not the diagnosis mix in every clinic.

Infographic chart showing glaucoma diagnoses among treated eyes in one study: primary open-angle glaucoma 45%, normal-tension glaucoma 22%, and exfoliation glaucoma 20%.
The study population included several glaucoma diagnoses, with primary open-angle glaucoma most common.

What happens during SLT

The SLT procedure begins with local anesthetic. Your ophthalmologist then places a lens on your eye to focus the laser and help keep blinking from interfering. The lens helps the doctor view the drainage angle clearly.

The laser is applied around the eye’s drainage angle. SLT causes very minimal discomfort and takes around 5 minutes per eye. Your experience can still vary with the condition of your eye and the treatment plan your ophthalmologist chooses.

SLT is typically painless or causes only minor discomfort.

Argon laser trabeculoplasty is an older laser comparison. Compared with SLT, argon laser trabeculoplasty requires 80 to 100 times more energy and generally cannot be repeated. Your eye-care professional can explain whether this comparison has any relevance to the treatment options being discussed for you. SLT was developed to provide the benefits of argon laser trabeculoplasty while causing fewer side effects. Level I studies found SLT and argon laser trabeculoplasty equivalent in safety and long-term efficacy. This evidence compares treatment results across studies; it does not identify the right laser or treatment plan for an individual eye.

Infographic stat row showing SLT takes around 5 minutes per eye and argon laser trabeculoplasty requires 80-100 times more energy than SLT. It contrasts procedure time with the older laser comparison.
SLT is described as a brief procedure and uses substantially less energy than argon laser treatment.

What to expect after SLT

Inflammation can occur after SLT, but it is not common. Compared with many other glaucoma treatments, including eye drops, other laser treatments, and surgery, SLT has few side effects. Minor, short-lived inflammation may follow SLT and may contribute to its pressure-lowering effect.

Your doctor may prescribe anti-inflammatory drops based on your situation. Do not start, stop, or change an eye medicine on your own after SLT. Follow the instructions given for your eyes, because the drops and monitoring plan can differ from another person’s plan.

Most patients have a follow-up visit within a few weeks so the doctor can reevaluate the eye. It may take up to 2 months for SLT to reach its full effect. Follow-up pressure checks help your ophthalmologist see whether the treatment is producing the intended change.

Before treatment, ask when your pressure will be checked, which symptoms should prompt a call, and whether you should continue your current glaucoma medicine. After treatment, keep the follow-up visit even if your eye feels comfortable. A temporary rise in eye pressure after SLT may require additional management, which is one reason the planned pressure check matters.

How long SLT may help

For most eyes, one SLT treatment may lower eye pressure for 2 to 3 years, and sometimes longer. This duration describes the possible period of pressure lowering after one treatment. It does not mean that every eye will respond for the same length of time.

Clinical studies reported that SLT’s pressure-lowering effect often lasted 24 months or longer. Other studies found that the response declined over time, so long-term effectiveness remains under investigation. Clinical evidence therefore supports monitoring over time rather than treating a reported duration as a fixed expiration date. A later pressure change can lead to a discussion of repeat SLT, medicine, or another treatment, depending on examination findings. High-quality support for SLT does not remove uncertainty about how long the benefit will last in your eyes.

A pressure reading at one visit cannot show the full duration of benefit. Your ophthalmologist compares pressure readings, optic nerve findings, and other glaucoma tests over time. If the effect fades, your plan may involve another treatment discussion rather than assuming the first treatment failed immediately.

Ask how long pressure control is expected to last in your treatment plan and which measurements will guide the next decision. Continue the follow-up schedule recommended for your glaucoma, even when the pressure result improves.

Stat row showing reported eye-pressure lowering duration after SLT: 2-3 years for most eyes after one treatment, and 24 months or longer in clinical studies. The figures describe possible duration, not a guarantee.
Reported benefit can last months to years, but responses differ between eyes.

What SLT can and cannot replace

The choice is not simply laser versus medicine for every person. For glaucoma, SLT may be discussed instead of pressure-lowering eye drops or alongside them.

SLT may control your eye pressure by itself, but you may still need glaucoma medicine as well. Do not stop pressure-lowering drops just because SLT has been performed. Continue the medicines and testing recommended for your eyes until your eye-care professional changes that plan. SLT may be thought of as equivalent to one glaucoma medication for controlling eye pressure. This comparison describes a pressure-lowering role, not a promise that one treatment will meet every person’s target. Pressure-lowering medicines and eye drops remain common treatment options, but poor compliance can limit treatment success and toxicity presents risks to consider. Those tradeoffs help explain why an ophthalmologist may discuss SLT, but they do not make laser preferable for every person.

SLT can be repeated if the first treatment was effective because the treatment leaves the drainage canals intact. Repeat treatment is a discussion for a later examination, not an automatic next step. A pressure change, the time since treatment, and your glaucoma findings all matter.

SLT is not a cure for glaucoma. The treatment lowers pressure as part of ongoing glaucoma care, while follow-up and testing help track the condition. If your pressure or vision concerns change, contact an eye-care professional rather than changing treatment on your own.

What clinical evidence supports

An American Academy of Ophthalmology evidence review found support for SLT’s long-term effectiveness as a primary treatment or as an add-on to glaucoma medicines in open-angle glaucoma. This supports SLT as a treatment option within glaucoma care. It does not determine whether the treatment fits your eyes. The American Academy of Ophthalmology evidence review included 30 studies that met its criteria: 19 received a level I rating and 11 received a level II rating. Those ratings describe the review’s evidence base, not whether SLT fits an individual eye. The American Academy of Ophthalmology evidence review searched literature in March 2020, September 2021, August 2022, and March 2023, then assessed 47 articles in full text and included 30.

A systematic review and meta-analysis examined 60 peer-reviewed clinical studies, with follow-up ranging from 12 to 60 months. The review found that SLT produced sustained eye-pressure reduction comparable to topical medicines within the 6- to 12-month interval. The comparison measures pressure reduction over that interval; it does not show that the treatments work identically for every person. The same analysis found a consistent reduction of nearly one medication per patient across multiple randomized trials. The LiGHT trial also reported lower cost and treatment burden with SLT than with medications and eye drops. These are study-level findings, so they do not establish that every patient can stop medication or will experience the same treatment burden.

One prospective study reported a 62.9% success rate at 12 months, defining success as at least a 30% reduction in eye pressure. The 62.9% figure measures the share of the study group meeting that definition at 12 months. Another trial found a sustained eye-pressure reduction of 5.2 mmHg in 72.5% of eyes one year after treatment; the 72.5% figure measures the share of eyes in that trial meeting the reported result.

These findings help explain why an ophthalmologist may discuss SLT for open-angle glaucoma. They do not replace your eye examination. Study results use defined groups, treatment settings, and follow-up periods, while your decision depends on your pressure readings, optic nerve status, drainage angle, and treatment history. SLT’s effectiveness may vary among different types of glaucoma and in people with high myopia, so a systematic review and meta-analysis emphasizes caution in those situations. This limitation gives your ophthalmologist another reason to match the procedure discussion to your glaucoma type and eye measurements rather than relying on a general success figure. The American Academy of Ophthalmology evidence review found SLT and argon laser trabeculoplasty equivalent in safety and long-term efficacy. That comparison helps place the older-laser discussion in context, but it does not select a treatment for an individual eye. Ask which outcome will guide the decision for your eyes: a pressure target, a percentage change, a measured pressure change, medication use, or duration of effect. These measures answer different questions and cannot be substituted for the pressure target set for your eyes.

Take these questions to your appointment:

  • What type of glaucoma or pressure problem are you treating?
  • What pressure target are you using for my eyes?
  • Would SLT be used alone, with drops, or after another treatment?
  • When will you check whether the treatment is working?
  • What should I do if my vision, comfort, or eye symptoms change?
  • Does my type of glaucoma or any high myopia change how you assess SLT?
  • How will you respond if eye pressure rises temporarily after treatment?
  • Which result will define success for my eyes: a percentage reduction, a pressure measurement, or another target?
Infographic chart showing reported clinical evidence: 62.9% success at 12 months, 72.5% of eyes with a 5.2 mmHg reduction one year after treatment, and 60 peer-reviewed clinical studies reviewed.
Clinical evidence includes both treatment-response rates and a broad review of published studies.

Side effects and risks to understand

Rarely, SLT can cause persistent inflammation inside the eye, which may lead to other eye problems. Rare complications reported after SLT include corneal swelling, bleeding inside the eye, and vision loss. These complications are not the usual short-lived effects, so persistent or worsening concerns need prompt professional attention. Other rare but serious adverse events reported with SLT include swelling in the macula, choroidal effusion, foveal burns, and changes in refraction. A small risk of a temporary rise in eye pressure exists shortly after SLT, and glaucoma medicines usually control it. Mild side effects can include soreness, redness, and blurred vision; these effects are usually very short-lived and can be treated with eye drops. Clinical complication data indicate that clinicians should adjust SLT for patients with high myopia because their risk is slightly elevated, although complications are rare.

Ask your ophthalmologist how your current eye condition affects the treatment discussion. The risk conversation should cover pressure monitoring, possible inflammation, medicine use, and what follow-up will look for. Do not use a general risk description to decide on treatment without an examination.

When to seek prompt eye care

Seek immediate qualified eye care for an ocular emergency. Please do not use our contact form for an ocular emergency. Use the emergency care route provided by your eye-care professional or local emergency service rather than waiting for a routine message response.

Arrange prompt eye-care guidance when you have personal questions about whether SLT fits your glaucoma, whether to continue a medicine, or when a follow-up check should occur. A medical record abbreviation cannot show your pressure target or the condition of your optic nerve. Those questions require a qualified professional who can examine your eyes.

SLT is not a cure, and appropriate follow-up and testing remain part of glaucoma care. Contact an eye-care professional promptly when your treatment instructions or symptoms are unclear.

Discuss the right next step for your eyes

SLT means selective laser trabeculoplasty, a laser treatment used to lower eye pressure in open-angle glaucoma. You can use that definition to understand a medical record, then ask about your pressure target, treatment choices, medicines, expected follow-up, and symptoms that need prompt attention. A qualified eye-care professional must decide whether SLT fits your eyes and treatment plan. At Northwest Eye in Minnetonka, we can discuss those questions during an eye-care visit.

Questions to ask about SLT

How long does it take for SLT to lower eye pressure?

SLT may take up to 2 months to reach its full effect, so pressure does not necessarily change immediately after treatment. Most patients have a follow-up visit within a few weeks, when the eye doctor can reassess pressure and the treatment plan. Keep that visit even if your eye feels comfortable.

Will I still need glaucoma eye drops after SLT?

Some patients control eye pressure with SLT alone, while others still need glaucoma medicine. Do not stop or change your drops without instructions from your eye-care professional. The decision depends on your pressure target, glaucoma findings, response to treatment, and follow-up measurements.

Can SLT be repeated if its effect wears off?

SLT can sometimes be repeated when the first treatment was effective because it leaves the eye’s drainage canals intact. Repeat treatment is not automatic. Your ophthalmologist considers your current pressure, glaucoma findings, previous response, and how long the benefit lasted before recommending another treatment.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information